High Court Approval of Verona Pharma Acquisition
In an important development for Verona Pharma, the High Court of Justice of England and Wales has granted approval for its acquisition by MSD, under the tradename of Merck & Co., Inc. This acquisition moves forward on the heels of a definitive agreement Verona Pharma entered into with MSD, emphasizing the growing interest in innovative biopharmaceutical solutions targeting respiratory diseases.
Overview of the Transaction
Verona Pharma has announced that MSD will acquire the company for approximately $10 billion, translating to a purchase price of $107 per American Depository Share (ADS). Each ADS represents eight ordinary shares of Verona Pharma, indicating a significant investment in the company's future.
Details of the Court Scheme
To facilitate this acquisition, the transaction is structured as a court-sanctioned scheme of arrangement, a method familiar within the framework of English law. The scheme has received the necessary sanction from the High Court, marking a key step toward finalizing the deal.
Timeline for Closing
The closing of the transaction is anticipated to occur shortly. Expected delivery of the Court Order to the Registrar of Companies is planned, which will bring the scheme into effect. Notably, trading of Verona ADSs on the Nasdaq will cease, with the last day of trading going forward without the company's shares.
Insights into Verona Pharma
Verona Pharma has been at the forefront of developing treatments for chronic respiratory diseases, addressing significant unmet medical needs. The company is particularly noted for its innovative therapies, including Ohtuvayre, which aims to offer new solutions for conditions like COPD.
Future Business Prospects
The acquisition by Merck signals a strong endorsement of Verona Pharma's potential, enhancing its ability to bring new therapies to market. With newly accessible resources and broader distribution networks, the synergy between these two companies is expected to expedite product development and commercialization efforts.
Statement from Company Executives
In the wake of the acquisition approval, Verona Pharma expressed excitement about joining forces with MSD. This partnership is seen as a significant opportunity to leverage Merck's extensive network and operational expertise, ultimately better serving patients with chronic respiratory conditions.
Company Contact Information
For additional information, please reach out to Verona Pharma's investor relations and communications teams:
Verona Pharma plc
Contact Number: +1-844-341-9901
Investor Relations: Victoria Stewart, Senior Director
Email: IR@veronapharma.com
Argot Partners
US Investor Inquiries
Contact Number: +1-212-600-1902
Email: verona@argotpartners.com
Ten Bridge Communications
International / US Media Inquiries
Contact Number: +1-781-316-4424
Email: tbcverona@tenbridgecommunications.com
Frequently Asked Questions
What is the acquisition price per share for Verona Pharma?
The acquisition price is set at $107 per American Depository Share.
Which company is acquiring Verona Pharma?
Verona Pharma is being acquired by MSD, the tradename of Merck & Co., Inc.
What is the total value of the transaction?
The total transaction value is approximately $10 billion.
When will the transaction officially close?
The transaction is expected to close upon the Court Order being delivered, projected for October 7, 2025.
What is the focus of Verona Pharma as a company?
Verona Pharma is focused on developing innovative therapies for chronic respiratory diseases.
